Caribou Biosciences (NASDAQ:CRBU) & Atyr PHARMA (NASDAQ:ATYR) Financial Survey

Caribou Biosciences (NASDAQ:CRBU) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Valuation and Earnings

This table compares Caribou Biosciences and Atyr PHARMA”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$34.48 million	3.73	-$102.07 million	($1.65)	-0.86
Atyr PHARMA	$350,000.00	928.14	-$50.39 million	($0.94)	-4.12

Atyr PHARMA has lower revenue, but higher earnings than Caribou Biosciences. Atyr PHARMA is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Caribou Biosciences and Atyr PHARMA, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	0	0	5	0	3.00
Atyr PHARMA	0	0	5	0	3.00

Caribou Biosciences presently has a consensus price target of $10.33, indicating a potential upside of 627.70%. Atyr PHARMA has a consensus price target of $19.25, indicating a potential upside of 397.42%. Given Caribou Biosciences’ higher possible upside, research analysts clearly believe Caribou Biosciences is more favorable than Atyr PHARMA.

Profitability

This table compares Caribou Biosciences and Atyr PHARMA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,290.81%	-45.46%	-38.07%
Atyr PHARMA	N/A	-79.44%	-59.16%

Institutional and Insider Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 9.5% of Caribou Biosciences shares are owned by insiders. Comparatively, 3.7% of Atyr PHARMA shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Caribou Biosciences has a beta of 2.31, meaning that its share price is 131% more volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Summary

Caribou Biosciences beats Atyr PHARMA on 8 of the 12 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About Atyr PHARMA

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.